Aardvark Therapeutics, Inc. Common Stock

NASDAQ:AARD

Biotechnology

Healthcare
$3.95 +2.36%

+$0.09 today

Market cap
$86.45M
Beta
4.47
P/E (TTM)
-1.2
EPS (TTM)
-$3.20
52W Low $3.35High $17.94

Volume 1.32M

Average 0.18M

Income Statement

Follow revenue through to earnings.

Revenue

$0.00

FY 2025 · Annual

Operating Income

-$62.73M

FY 2025 · Annual

Net Income

-$57.59M

FY 2025 · Annual

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0000
Cost of Revenue0000
Gross Profit0000
Gross Margin————
Research & Development7.17M4.48M17.36M48.94M
Selling, General & Admin2.7M2.17M5.31M13.79M
Operating Expenses11.36M7.42M22.79M62.73M
Depreciation & Amortization110K97K16K36K
EBITDA(10.76M)(6.56M)(22.65M)(57.56M)
EBITDA Margin————
Operating Income(11.36M)(7.42M)(22.79M)(62.73M)
Operating Margin————
Interest Income120K1.42M2.41M5.14M
Interest Expense0000
Other Income / Expenses(2.2M)207K2.2M5.13M
Income Before Tax(13.56M)(7.21M)(20.59M)(57.59M)
Pre-Tax Margin————
Income Tax Expense0000
Net Income(13.56M)(7.21M)(20.59M)(57.59M)
Net Margin————
EPS (Basic)(0.63)(0.34)(0.95)(2.64)
EPS (Diluted)(0.63)(0.34)(0.95)(2.64)
Weighted Avg Shares21.38M21.38M21.7M21.82M
Weighted Avg Shares (Diluted)21.38M21.38M21.7M21.82M

AARD Earnings Waterfall · TTM

NASDAQ:AARD · Revenue to Net Income

Key Ratios

EPS$-3.21
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-3.6
P/S Ratio0.0

Analysis

$0 of revenue converted into -$69.9M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-3.21, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipOct 8, 2026
8-KCurrent reportOct 8, 2026
3Initial statement of beneficial ownershipOct 8, 2026
4Statement of changes in beneficial ownershipSep 11, 2026
4Statement of changes in beneficial ownershipAug 21, 2026

How much revenue does AARD generate?

Aardvark Therapeutics, Inc. Common Stock (AARD) reported $0.00 of revenue in fiscal 2025.

Is AARD profitable?

Aardvark Therapeutics, Inc. Common Stock (AARD) reported -$57.59M of net income.